QureTech Bio

Quretech Bio - defeats bacterial virulence

Since World War II, antibiotics have been the most effective factor in longevity and population expansion. Today, loss of effective antibiotics threatens our medical institutions – antibiotic resistance is a serious problem already or will be within the decade. Doctors, in the US and UK, have reported that they now have less than a handful effective antibiotics for some pathogens. In the EU alone, infections with multidrug resistant bacteria cause around 25,000 deaths each year and the associated economic burden is immense. Still in today’s world, more infants and children are dying from pneumonia than from malaria.

QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. The global market for antibiotics is estimated at USD 38 billion with USA, Europe and Japan representing 50%. The cost of antibiotic resistance to medical communities in the EU alone is conservatively estimated to be €1.5 billion and the availability of new targeted antibiotics of this type would generate significant cost savings for healthcare systems.

New types of antibiotics to tackle resistant bacteria are urgently needed, yet there is an almost empty drug pipeline with few early stage drugs under development. Scientific and industrial communities must develop new antibiotic drugs, and there must be a drive towards developing novel antibiotics with alternative modes of action.

Hult1

Current projects

Mycket spännande klinisk studs håller på att startas. Behandlingar av tuberkulos består alltid av kombinationer av olika antibiotikum. Det krävs för att komma åt denna besvärliga bakterie.
QureTech Bio's angreppssätt är att försvaga bakteriens försvarssystem och därigenom göra den avsevärt mer sårbar för annan antibiotika. Det är alltså inte frågan om antingen eller, det är frågan om vilka kombinationer som ger bäst resultat. Det är där QureTech Bio har en unik lösning.
... See MoreSee Less

Organisationen Läkare utan gränser inleder kliniska studier för att pröva nya tuberkulosläkemedel. www.lakemedelsvarlden.se/ny-behandling-av-resistent-tuberkulos-provas/

View on Facebook